Voyager Therapeutics, Inc. (VYGR) fundamentals score
Voyager Therapeutics is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 2.8 out of 10, Unhealthy fundamentals
- Growth: 2.0/10
- Profitability: 1.0/10
- Financial health: 5.5/10
- Earnings quality: 3.3/10
- Valuation: 2.9/10
Scores are calculated from Voyager Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10